{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mistegard CE"],"funding":["Graduate School of HEALTH, Aarhus University","Aase and Ejnar Danielsen Foundation","The Danish National Research Foundation through the Center for Cellular Signal Patterns","Danish Rheumatism Association"],"pagination":["e004127"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11328660"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(2)"],"pubmed_abstract":["<h4>Objectives</h4>To investigate lectin pathway proteins (LPPs) as biomarkers for axial spondyloarthritis (axSpA) in a cross-sectional cohort with a suspicion of axSpA, comprising newly diagnosed axSpA and chronic low back pain (cLBP) individuals.<h4>Methods</h4>Serum samples from 515 participants within the OptiRef cohort, including 151 axSpA patients and 364 cLBP patients, were measured using immunoassays for LPPs (mannan-binding lectin (MBL), collectin liver-1 (CL-L1), M-ficolin, H-ficolin and L-ficolin, MBL-associated serine proteases (MASP)-1, -2 and -3, MBL-associated proteins (MAp19 and MAp44) and the complement activation product C3dg).<h4>Results</h4>Serum levels of L-ficolin, MASP-2 and C3dg were elevated in axSpA patients, whereas levels of MASP-3 and CL-L1 were decreased, and "],"journal":["RMD open"],"pubmed_title":["Exploring complement biomarkers in suspected axial spondyloarthritis."],"pmcid":["PMC11328660"],"funding_grant_id":["DNRF135","A6093 and A6462"],"pubmed_authors":["Mistegard CE","Loft AG","Luders S","Proft F","Protopopov M","Troldborg A","Spiller L","Rios Rodriguez V","Muche B","Weber AK","Rademacher J","Thiel S","Sieper J","Poddubnyy D"],"additional_accession":[]},"is_claimable":false,"name":"Exploring complement biomarkers in suspected axial spondyloarthritis.","description":"<h4>Objectives</h4>To investigate lectin pathway proteins (LPPs) as biomarkers for axial spondyloarthritis (axSpA) in a cross-sectional cohort with a suspicion of axSpA, comprising newly diagnosed axSpA and chronic low back pain (cLBP) individuals.<h4>Methods</h4>Serum samples from 515 participants within the OptiRef cohort, including 151 axSpA patients and 364 cLBP patients, were measured using immunoassays for LPPs (mannan-binding lectin (MBL), collectin liver-1 (CL-L1), M-ficolin, H-ficolin and L-ficolin, MBL-associated serine proteases (MASP)-1, -2 and -3, MBL-associated proteins (MAp19 and MAp44) and the complement activation product C3dg).<h4>Results</h4>Serum levels of L-ficolin, MASP-2 and C3dg were elevated in axSpA patients, whereas levels of MASP-3 and CL-L1 were decreased, and ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2025-04-19T20:41:35.466Z","creation":"2025-04-19T20:41:35.466Z"},"accession":"S-EPMC11328660","cross_references":{"pubmed":["38749532"],"doi":["10.1136/rmdopen-2024-004127"]}}